What Is DSIP? Delta Sleep-Inducing Peptide

DSIP, delta sleep-inducing peptide, is a nonapeptide first isolated from the cerebral venous blood of rabbits in 1977 by researchers Schoenenberger and Monnier in Basel. It takes its name from the electroencephalogram (EEG) delta-wave activity the isolated fraction produced in that early animal work, not from any established mechanism in humans. Since then it has been used as a research tool in a range of animal and cell-based studies, and its receptor has still not been identified.

DSIP at a glance

Attribute	Detail
Class	Linear nonapeptide (9 amino acid residues)
Sequence	Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, free N- and C-termini
First isolated	1977, from dialyzed cerebral venous blood of rabbits given hypnogenic thalamic stimulation
Naming basis	Enhancement of delta and spindle EEG activity observed in the original rabbit infusion experiments
What later studies examined	Stress-related limbic activation, hypothalamic-pituitary-adrenal (HPA) axis markers, and receptor pharmacology, in animal and in vitro models, with some human physiology testing
Receptor status	Not identified; gene and precursor protein also not established
Form supplied	Lyophilized (freeze-dried) powder for laboratory reconstitution

How was DSIP discovered?

DSIP was isolated by Schoenenberger and Monnier and reported in a 1977 paper in the Proceedings of the National Academy of Sciences. The researchers applied low-frequency, "hypnogenic" electrical stimulation to the intralaminar thalamic nuclei of rabbits, a stimulus previously associated with the appearance of slow-wave (delta) EEG activity, then collected and dialyzed cerebral venous blood from those animals. From that dialysate they purified a peptide fraction which, when infused into the brain ventricles of recipient rabbits, was reported to reproduce delta and spindle EEG activity under double-blind conditions across dozens of animals. The purified fraction was named delta sleep-inducing peptide on that basis (Schoenenberger and Monnier, 1977).

What is the chemical structure of DSIP?

Follow-up amino-acid analysis and sequencing work by the same research group, published the following year, established DSIP as a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, with free amino and carboxyl termini (Schoenenberger et al., 1978). The paper also reported synthesis of the nonapeptide along with several possible metabolic fragments and analogues, which were then compared for activity in the same rabbit infusion model used in the original isolation study. As a short linear peptide with no disulfide bridges or branching, DSIP is chemically simple relative to many of the cyclic or backbone-modified peptides used in laboratory research.

Why is it called a "delta sleep-inducing" peptide?

The name reflects the endpoint measured in the original 1977 and 1978 experiments, an increase in delta-band EEG activity and spindle activity after intraventricular infusion in rabbits, not a demonstrated sleep mechanism in humans. Subsequent reviewers have been explicit that this naming has not held up well under further scrutiny. A 2006 review in the Journal of Neurochemistry, published almost three decades after the original isolation, described the peptide as "a still unresolved riddle" and characterized the evidence for a specific sleep-inducing role as weak (Kovalzon and Strekalova, 2006). An earlier 1986 review in the journal Peptides had already catalogued a wide and sometimes inconsistent set of reported effects across species and paradigms, underscoring that the original name was assigned early in the peptide's research history and has stayed attached to it since (Graf and Kastin, 1986).

What have later studies examined?

In the decades following its isolation, DSIP became a tool compound in several unrelated lines of research, most of them in animal models or in vitro systems rather than in any approved clinical context.

Stress and limbic activation models

One rat study examined how intraperitoneal administration of DSIP and of an ACTH(4-10) analogue affected Fos protein expression, a marker of neuronal activation, in limbic brain structures during emotional stress, comparing animals with different individual stress reactivity (Sudakov et al., 2001). The study reported changes in Fos induction patterns across the structures examined and discussed the findings in the context of the neurophysiology of the stress response in the rat, not any outcome in humans.

Endocrine and HPA axis studies

DSIP has also been examined for effects on hormones of the hypothalamic-pituitary-adrenal axis, with mixed results depending on the model. In one in vitro study using rat anterior pituitary tissue, DSIP was reported to reduce corticotropin-releasing factor (CRF)-induced corticosterone release (Graf et al., 1985). In a separate human physiology study that measured ACTH and cortisol responses to CRH infusion and to a standard meal, DSIP infusion produced results that were reported as statistically indistinguishable from placebo (Spath-Schwalbe et al., 1995). Taken together, the two studies illustrate that reported endocrine effects have not been consistent across model systems, which is a recurring theme in the DSIP literature.

CNS and receptor pharmacology

A substantial share of the research interest in DSIP has gone toward identifying how, mechanistically, it produces any of its reported effects. The 1986 update in Peptides and the 2006 Journal of Neurochemistry review both surveyed proposed central nervous system mechanisms, and both noted that no specific, well-characterized DSIP receptor had been isolated at the time of writing (Graf and Kastin, 1986; Kovalzon and Strekalova, 2006).

What remains unresolved about DSIP?

Several basic questions about DSIP remain open in the published literature. The gene encoding DSIP, and any larger precursor protein it might be cleaved from, has not been established. No specific receptor for the peptide has been isolated or characterized. And the original sleep-related interpretation of the 1977 and 1978 EEG findings has been described by later reviewers as poorly supported by the subsequent, sometimes contradictory, body of work (Kovalzon and Strekalova, 2006). Researchers citing DSIP studies should treat the peptide's name as a historical label tied to a specific set of 1970s animal EEG experiments, rather than as a description of a confirmed mechanism.

How is DSIP supplied and handled in the lab?

Like most short synthetic peptides used in research, DSIP is supplied as a lyophilized powder and requires standard bench handling to preserve its integrity: keeping the sealed vial protected from light and moisture, allowing it to reach room temperature before opening to limit condensation, and using appropriate low-temperature storage once reconstituted. General principles for lyophilized peptide storage, freeze-thaw avoidance, and cold-chain handling are covered in more depth in our guide to peptide storage and stability. For the reconstitution math itself, working out volumes and concentrations from a vial's labeled mass, see our step-by-step guide to reconstituting lyophilized peptides. As with any research peptide, a certificate of analysis should be checked against the vial before use; our guide on how to read a peptide certificate of analysis covers what each section of a COA verifies. A full research summary and current specifications for this compound are maintained on the DSIP research library page, and lots are available on the DSIP product page for laboratory ordering.

Frequently asked questions

Is DSIP a naturally occurring peptide?

It was isolated from rabbit blood as a naturally present fraction in the original 1977 work, and immunoreactive material resembling DSIP has been reported in other species since. However, the gene encoding it and its biosynthetic origin have not been definitively established in the literature.

What does "nonapeptide" mean?

A nonapeptide is a peptide built from nine amino acid residues joined by peptide bonds. DSIP's nine residues, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, were determined by amino-acid analysis and sequencing published in 1978.

Has a DSIP receptor been identified?

No. Review articles spanning from 1986 to 2006 consistently report that no specific DSIP receptor has been isolated or pharmacologically characterized, which is one of the more frequently cited open questions in the peptide's research history.

Why do some sources describe DSIP's effects as inconsistent?

Because published studies examining DSIP in different models, such as rat pituitary tissue versus human CRH-infusion testing, have reported different outcomes for related endpoints like corticosterone or ACTH and cortisol release. Reviewers have pointed to this lack of consistency across model systems as one reason the peptide's mechanism remains unresolved.

Is DSIP the same as a sleep medication?

No. DSIP is a research peptide, not an approved drug or medication of any kind. Its name reflects an EEG measurement made in 1970s rabbit experiments, and the studies summarized here were conducted in animal, in vitro, or non-clinical human physiology settings for research purposes.

How should DSIP be stored between uses?

General lyophilized-peptide handling practices apply: keep the sealed vial cold, dark, and dry, and minimize freeze-thaw cycles once reconstituted. See our peptide storage and stability guide for the underlying principles.

References

Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.